1. Αρχική σελίδα
  2. Αναζήτηση

Efficacy of atezolizumab–bevacizumab combination therapy early after recurrence of hepatocellular carcinoma following resection or ablation with a curative intent

Το τεκμήριο παρέχεται από τον φορέα :
Ελληνική Γαστροεντερολογική Εταιρία   

Αποθετήριο :
Annals of Gastroenterology   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



Efficacy of atezolizumab–bevacizumab combination therapy early after recurrence of hepatocellular carcinoma following resection or ablation with a curative intent (EN)
Sidiropoulos, Orestis
Elefsiniotis, Ioannis
Pantzios, Spyridon
Syriha, Antonia
Rellou, Sofia
Korkolis, Dimitris P.
Sotiropoulos, Georgios C.
Stathopoulou, Ioanna
Barla, Georgia
Ptohis, Nikolaos
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
2024-11-20
Background The pattern of hepatocellular carcinoma (HCC) recurrence after resection/ablation is intrahepatic and/or systemic. The efficacy of atezolizumab–bevacizumab treatment as early therapy after recurrence has not been extensively evaluated. Methods We evaluated 32 patients (group A) with early HCC recurrence after resection/ablation and 24 patients (group B) initially diagnosed as Barcelona Clinic Liver Cancer (BCLC)-C, all treated with atezolizumab–bevacizumab. Group A was subdivided in group A1 (progression to BCLC-C, n=14) and group A2 (progression to BCLC-B, n=18). Results Groups A1/A2 were comparable for all baseline parameters. Objective response was observed in 14.3% and 33.3% of patients in groups A1 and A2, respectively. Median overall survival (OS) was impressive and comparable between the 2 groups (22 and 26 months, respectively, P=0.71), as was median progression-free survival (PFS) (15 and 6 months, respectively, P=0.126). Patients categorized in the advanced stage (groups A1/B) were comparable for all baseline characteristics. Median OS was significantly higher in group A1 compared to B (26 vs. 6 months, P<0.001), as was median PFS (6 vs. 3 months, P=0.086). Conclusions Early initiation of atezolizumab–bevacizumab after recurrence following curative therapy results in impressive survival rates, irrespective of recurrence pattern. Survival of atezolizumab–bevacizumab treated patients who were initially diagnosed in the BCLC-C stage is significantly different from those who recurred to BCLC-C following potentially curative therapies. Keywords Hepatocellular carcinoma, recurrence, resection, ablation, atezolizumab–bevacizumab Ann Gastroenterol 2024; 37 (6): 708-717 (EN)
Αγγλική γλώσσα
Hellenic Society of Gastroenterology (EN)
1792-7463
1108-7471
Annals of Gastroenterology; Volume 37, No 6 (2024); 708 (EN)
Copyright (c) 2024 Annals of Gastroenterology (EN)
Ελληνική Γαστροεντερολογική Εταιρία
Annals of Gastroenterology
Original Articles



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.